Allogene Highlights Positive Interim ALPHA3 CAR T Data

The latest update is out from Allogene Therapeutics ( (ALLO) ).

On April 13, 2026, Allogene Therapeutics reported an interim futility analysis from its pivotal Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel as a first‑line consolidation therapy for high‑risk large B‑cell lymphoma, using Natera’s CLARITY MRD assay to guide intervention before clinical relapse. Among the first 24 randomized patients, 58.3% in the cema‑cel arm achieved MRD negativity versus 16.7% under observation, with rapid ctDNA clearance and a generally favorable safety profile showing no treatment‑related serious adverse events or typical CAR T toxicities, positioning the program as a potentially differentiated, outpatient‑feasible CAR T approach ahead of planned interim and primary event‑free survival analyses in 2027 and 2028.

Although based on small numbers and with efficacy endpoints still blinded, the sizable MRD clearance difference and low rates of serious toxicity suggest cema‑cel could offer meaningful clinical benefit in a high‑risk population that currently relapses frequently after front‑line therapy. Successful completion of the roughly 220‑patient ALPHA3 study across more than 60 sites, and positive event‑free survival results, could support a future biologics license application and strengthen Allogene’s competitive position in next‑generation lymphoma treatment by shifting CAR T use earlier in the treatment paradigm.

The most recent analyst rating on (ALLO) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Allogene Therapeutics stock, see the ALLO Stock Forecast page.

Spark’s Take on ALLO Stock

According to Spark, TipRanks’ AI Analyst, ALLO is a Neutral.

The score is held back primarily by very weak financial performance (minimal revenue, persistent losses, and sustained cash burn). Offsetting this, the latest earnings call points to meaningful upcoming catalysts and an extended cash runway, while technicals are moderately supportive with an intermediate uptrend but limited near-term momentum. Valuation metrics provide little support due to negative earnings and no dividend.

To see Spark’s full report on ALLO stock, click here.

More about Allogene Therapeutics

Allogene Therapeutics, Inc. is a biotechnology company focused on developing off‑the‑shelf allogeneic CAR T cell therapies for cancer. Its pipeline targets hematologic malignancies such as large B‑cell lymphoma, with an emphasis on using advanced molecular tools like minimal residual disease assays to better select and treat high‑risk patients in earlier lines of therapy.

Average Trading Volume: 5,835,274

Technical Sentiment Signal: Buy

Current Market Cap: $663.1M

Find detailed analytics on ALLO stock on TipRanks’ Stock Analysis page.